Delivery Order SPE2DB20D2104-SPE2DB25FMXLB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $47,262.06 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 12, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the vendor's demonstrated capability to compete openly for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 mL pens valued at $4,237.92 with a firm fixed price structure. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $7,945.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 11, 2025, with a completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply framework. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a $43,038.15 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 mL pens with an ultimate completion date of August 11, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award for pharmaceutical supply to support federal medical procurement needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $66,460.68 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and carries an ultimate completion date of August 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this delivery order, with performance taking place at the company's Conshohocken...
- The Defense Logistics Agency awarded a $18,415.47 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and represents a direct delivery of pharmaceutical products to support federal healthcare operations. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL pens, with a contract ceiling value of $52,595.52 and an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- On August 5, 2025, the Defense Logistics Agency awarded a delivery order valued at $48,364.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections. This firm fixed-price delivery order, which is not set-aside designated, represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The products will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $14,934.34 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $44,236.34 on July 25, 2025, for the supply of Dupixent 300 mg/2 mL pens. This firm fixed-price delivery order, with an ultimate completion date of July 28, 2025, represents a competitive award with no set-aside designation. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXLBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pens valued at $9,541.38 under a firm fixed-price contract. This non-set-aside delivery order is scheduled for completion by August 12, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement within DLA's medical supply chain operations. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999 and extends through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical federal vendor supplying medications, vaccines, medical devices, and specialized healthcare commodities to military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill competitive federal procurement requirements across a wide spectrum of therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.5k | 8/11/25 |